Advances in synthesis of pimavanserin
10.13220/j.cnki.jipr.2016.04.019
- Author:
Run GAN
1
Author Information
1. Department of Pharmacy, Chongqing Medical University
- Publication Type:Journal Article
- Keywords:
Drug of 5-HT2A receptor;
Parkinson’s diseases;
Pimavanserin;
Synthesis
- From:
Journal of International Pharmaceutical Research
2016;43(4):688-691
- CountryChina
- Language:Chinese
-
Abstract:
Pimavanserin(Nuplazid) is a drug of selective targeting 5-HT2A receptor, developed by Acadia Pharmaceuticals. In April 29, 2016, it was approved by FDA for the treatment of Parkinson’s disease (PD) patients experiencing mental symptoms such as hallucinations and delusions. In this paper, we summarize the synthetic methods of pimavanserin published in literature in recent years and their advantages and disadvantages.
